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Several studies report immunomodulatory eﬀects of endogenous IL-10 after trauma. The present study investigates the eﬀect
of inhalative IL-10 administration on systemic and pulmonary inﬂammation in hemorrhagic shock. Male C57/BL6 mice (8
animals per group) were subjected to pressure-controlled hemorrhagic shock for 1.5hrs followed by resuscitation and inhalative
administration of either 50μL PBS (Shock group) or 50μg/kg recombinant mouse IL-10 dissolved in 50μLP B S( S h o c k+I L - 1 0
group).Animalsweresacriﬁcedafter4.5hrsofrecoveryandserumIL-6,IL-10,KC,andMCP-1concentrationsweremeasuredwith
ELISA kits. Acute pulmonary inﬂammation was assessed by pulmonary myeloperoxidase (MPO) activity and pulmonary H&E
histopathology. Inhalative IL-10 administration decreased pulmonary inﬂammation without altering the systemic concentrations
of IL-6, IL-10, and KC. Serum MCP-1 levels were signiﬁcantly reduced following inhalative IL-10 administration. These ﬁndings
suggest that inhalative IL-10 administration may modulate the pulmonary microenvironment without major alterations of the
systemic inﬂammatory response, thus minimizing the potential susceptibility to infection and sepsis.
1.Introduction
Hemorrhagic shock initiates a systemic inﬂammatory re-
sponse which is thought to be responsible for the devel-
opment of ARDS and MOF [1]. The pharmacological
modulation of this excessive and uncontrolled release of pro-
inﬂammatory cytokines is considered a promising therapeu-
tic strategy [2]. Previous studies have shown that the admin-
istration of IL-10 following hemorrhagic shock is capable
of reducing systemic and pulmonary inﬂammation [3, 4].
However, an early inhibition of the systemic inﬂammatory
response may result in increased rates of infection and
sepsis [5–10]. This concern may be diminished by immuno-
modulating strategies that target hyperinﬂammation in
speciﬁc organs, but leave systemic inﬂammatory responses
unabated. In view of these demands, we hypothesized that
inhalative administration of IL-10 following hemorrhagic
shock would attenuate the pulmonary but not the systemic
inﬂammatory response.
2.MaterialsandMethods
2.1. Animal Care. This research protocol complied with
the regulations regarding the care and use of experimental
animals published by the NIH and was approved by the
Institutional Animal Use and Care Committee of the RWTH
Aachen University. Male C57/BL6 mice (Charles Rivers
Laboratories, Germany), 6–10 weeks old and weighing 20–
30g, were used in the experiments. The animals were
maintained in the Animal Research Center of the RWTH
Aachen University with a 12:12 h light-dark cycle and free
access to standard laboratory feed and water. Animals were
anesthetized with inhaled isoﬂurane (Abbott Laboratories,2 Mediators of Inﬂammation
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Figure 1:ComparisonofserumIL-6(a),IL-10(b),KC(c),andMCP-1(d)levelsinC57/BL6micefollowinghemorrhagicshockwith(Shock
+ IL-10) or without (Shock) inhalative administration of IL-10. Results are expressed as means ± SD of 8 animals per group (
∗P < 0.05
versus Control; #P < 0.05 versus Sham; +P < 0.05 versus Shock + IL-10).
Wiesbaden, Germany), 70mg/kg i.p. pentobarbital (Merial
GmbH, Hallbergmoos, Germany), and 0.5mg/kg buprenor-
phine (Reckitt-Benckiser, Bergheim, Germany).
2.2. Groups. C57/BL6 mice were divided into four groups. In
the Control group (n = 8), animals were euthanized after
the induction of anaesthesia to obtain physiological baseline
levels. Animals in the Sham group (n = 8) were subjected
to femoral artery catheterization, 1.5hrs of anaesthesia, and
4.5hrs of recovery before euthanasia. Animals of the Shock
(n = 8) or Shock + IL-10 (n = 8) group were subjected
to femoral artery catheterization, 1.5hrs of anaesthesia with
pressure-controlled hemorrhagic shock followed by inhala-
tive administration of either 50μL phosphate buﬀered saline
(PBS) or 50μg/kg recombinant mouse IL-10 (Cys 149 Typ,
R&D Systems) dissolved in 50μL PBS. The animals were
sacriﬁced after 4.5hrs of recovery.
2.3. Femoral Artery Cannulation and Induction of Hem-
orrhagic Shock. Animals were subjected to anesthesia as
described above. A sterile technique was used to perform a
left groin exploration, and the left femoral artery was can-
nulated with tapered polyethylene-10 tubing. The catheter
was connected to a digital blood pressure monitor (TSE
Systems, Bad Homburg, Germany) and the mean arterial
pressure (MAP) was recorded. Pressure-controlled hemor-
rhagic shock was performed by withdrawing blood over
a period of 15min in a syringe with 0.07mL of heparin
(1000 USP units/mL) until a MAP of 35mmHg was reached.
Hemorrhagic shock was maintained for 1.5hrs followed by
resuscitation with shed blood and an equal volume of 0.9%
saline. The catheter was removed, the artery ligated, and the
skin incision closed. After a recovery phase of 4.5hrs the
animals were sacriﬁced.
2.4. Administration of Inhalative IL-10. The inhalative ad-
ministration of PBS or IL-10 was performed using a
MicroSprayer Aeroliser (Penn-Century, Philadelphia, Pa,
USA) connected to a high-pressure syringe (FMJ-250, Penn-
Century, Philadelphia, Pa, USA). The endotracheal intuba-
tion was carried out as described by Bivas-Benita et al. [11].
Brieﬂy, the mouth was opened with a blunt forceps and the
tongue was pulled out and moved to the left in order to
visualise the trachea. The MicroSprayer was inserted intoMediators of Inﬂammation 3
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Figure 2: Pulmonary myeloperoxidase (MPO) activity in C57/BL6
mice following hemorrhagic shock with (Shock + IL-10) or without
(Shock) inhalative administration of IL-10. Results are expressed as
means ± SD of 8 animals per group (
∗P < 0.05 versus Control;
#P < 0.05 versus Sham; +P < 0.05 versus Shock + IL-10).
trachea. Once intubation was completed PBS or IL-10 was
administered as aerosol. The deposition of aerosols into the
small airways using this method has been validated with
ﬂuorescent nanoparticles [11].
2.5. Blood Collection for Serum Cytokines. Following thora-
cotomy, cardiac blood was withdrawn under deep anesthesia
as part of the procedure of exsanguination for euthanasia.
Plasma samples were allowed to clot at 4◦C and then were
centrifuged at 7000rpm for 7min in order to separate the
serum from cellular blood components. Serum was stored
at −20◦C until thawed for further evaluation. Serum IL-6,
IL-10, MCP-1, and KC levels were quantiﬁed with ELISA
kits (R&D System Inc., Minneapolis, Minn, USA) as per
manufacturer’s speciﬁcations.
2.6. Pulmonary Myeloperoxidase (MPO) Activity. To mini-
mize background MPO activity by remaining nonadherent
intravascular polymorphonuclear cells, a needle was inserted
into the beating right ventricle, after withdrawal of cardiac
blood, and the circulation was perfused with 1.5mL of
PBS. The left lung was harvested and immediately snapped-
frozen in liquid nitrogen and stored at −80◦ Celsius. To
determine tissue MPO activity, the samples were thawed and
homogenized in a lysis buﬀer according to the manufac-
t u r e r ’ sp r o t o c o l .T h eM P Oa c t i v i t yw a sm e a s u r e du s i n ga n
MPO-ELISA kit (Hycultec GmbH, Beutelsbach, Germany)
and normalized to the protein concentration of the sample
(BCA Protein Assay Kit, Pierce, Rockford, Ill, USA).
2.7. Pulmonary Histopathology. For the detection of pul-
monary inﬂammation and lung injury the right lung was
harvested and immediately ﬁxed in buﬀered formalin.
Paraﬃn-embedded blocks were cut at 5μm thickness and
stained with H&E (Hematoxylin and Eosin).
2.8. Statistical Analysis. All results in this paper are expressed
as the mean ± SD of eight animals per group. Data were
transformed by the BoxCox transformation (JMP 5.0.1 for
Windows). In normally distributed variables group compar-
isons were assessed using ANOVA followed by Tukey’s HSD
test. Nonnormally distributed parameters were tested using
the Kruskal-Wallis-Test. The null hypothesis was rejected for
P<0.05. Data were analysed using SPSS Version 18 (SPSS,
Chicago, Ill, USA).
3. Results
3.1. Serum Cytokine Levels. Serum IL-6 levels were signiﬁ-
cantly higher in animals subjected to hemorrhagic shock as
comparedtoControlandShamanimals.However,theserum
IL-6 concentration was indistinguishable between Shock
and Shock + IL-10 animals, thus inhalative IL-10 did not
signiﬁcantly alter systemic IL-6 levels (Figure 1(a)).
Serum IL-10 concentrations showed an increase follow-
ing hemorrhagic shock; however this did not reach statistical
signiﬁcance. Inhalative IL-10 was not associated with a
signiﬁcant increase in systemic IL-10 levels (Figure 1(b)).
Serum KC levels were signiﬁcantly increased in Shock
and Shock + IL-10 animals as compared with Control and
Sham mice. There was no signiﬁcant diﬀerence in serum KC
levels between Shock and Shock + IL-10 mice (Figure 1(c)).
Serum MCP-1 levels were signiﬁcantly higher following
hemorrhagic shock as compared to Control and Sham
animals. Furthermore, the MCP-1 concentration was signif-
icantly reduced in animals with inhalative IL-10 adminis-
tration, thus inhalative IL-10 alters systemic MCP-1 levels
(Figure 1(d)).
3.2. Pulmonary Inﬂammation. Pulmonary MPO activity was
signiﬁcantly higher in the Shock and Shock + IL-10 group
as compared with Control and Sham animals. Inhalative
IL-10 signiﬁcantly reduced the pulmonary MPO activity as
compared to Shock animals (Figure 2).
This eﬀect was conﬁrmed by histology which showed
a reduced pulmonary inﬁltration with inﬂammatory cells
(Figure 3).
4. Discussion
The immunoregulatory potential of IL-10 is well recognized
and a potential role of IL-10 as a therapeutic agent is increas-
ingly investigated in various animal models [3, 4, 12–14]
and human studies [12]. Beneﬁcial eﬀects of early systemic
IL-10 release following injury have been reported [3, 15],
mainlyrelatedtotheinhibitionofproinﬂammatorycytokine
synthesis [16, 17] and leukocyte recruitment [18]. However,
especially in the later course following trauma, the incidence
of infection is strongly associated with systemic IL-10 con-
centrations [5–10] .T h u s ,s y s t e m i cI L - 1 0i sad o u b l e - e d g e d
sword in treating severe trauma: potentially beneﬁcial in
the early but deleterious in the later phase. This conun-
drum raises the possibility whether locally applied IL-10
strategy could possibly protect end organs by changing
their inﬂammatory microenvironment without altering the
systemic inﬂammatory response and the susceptibility to4 Mediators of Inﬂammation
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Figure 3: Representative H&E (Hematoxylin and Eosin) lung histology (20x) of the Control (a), Shock (b), and Shock + IL-10 (c) group
4.5hrs after resuscitation. Inhalative IL-10 reduces the pulmonary inﬂux of inﬂammatory cells.
infection and sepsis. The lung is frequently aﬀected by
systemic inﬂammation and the development of acute lung
injury seems to be associated with local and systemic IL-10
concentrations, examples are hemorrhage [3, 4], peritonitis
[19], or major surgery [20]. Low IL-10 concentrations in the
BAL of patients already suﬀering from ARDS were correlated
with an increased mortality rate [21], whereas patients
having an IL-10 polymorphism with increased IL-10 release
showed a decreased incidence of ARDS [22]. Given that
hemorrhagic shock impairs the induction of IL-10 expres-
sion by alveolar macrophages [23] and that systemic IL-10
administration attenuates pulmonary but not hepatic injury
[4, 13], we hypothesized that a local repletion of pulmonary
IL-10 following hemorrhagic reduces pulmonary inﬂamma-
tion without altering the systemic inﬂammatory response.
Trauma hemorrhage is well known to lead to pulmonary
inﬂammation and leukocyte inﬁltration, that is at least in
part mediated by KC [24]. In the present study, we observed
signiﬁcant increases of systemic IL-6 and KC concentrations
following hemorrhagic shock and both eﬀects were not
alteredbyinhalativeIL-10administration.Theseﬁndingsare
incontrasttostudiesreportingsigniﬁcantlyreducedsystemic
IL-6 and KC levels in hemorrhagic shock following intra-
arterial, intraperitoneal, or subcutaneous IL-10 administra-
tion [3, 13, 25]. These ﬁndings support our hypothesis that
inhalativeadministeredIL-10mainlyaﬀectsthelungwithout
major alterations of the systemic inﬂammatory response.
This is in accordance with no detectable diﬀerences of
systemic IL-10 concentrations between animals subjected
to hemorrhagic shock with or without inhalative IL-10,
although we cannot exclude an earlier systemic IL-10 peak,
due to the short half-life of IL-10.
Interestingly, we observed a signiﬁcant reduction of sys-
temic MCP-1 following inhalative IL-10 application. MCP-
1 is a major attractant for macrophages and monocytes
and is upregulated following trauma hemorrhage [26]. An
explanationforreducedsystemicMCP-1concentrationsmay
lie in the role of alveolar macrophages which secrete MCP-1
and thereby potentiate inﬂammatory triggered lung injury
[27, 28]. Thus systemic measured MCP-1 levels following
hemorrhagic shock may be derived from the secretion of
alveolar macrophages.
We have previously observed these speciﬁc modulations
of chemokine release in a model of IL-10 KO mice [4].
Herein, IL-10 deﬁciency signiﬁcantly increased systemic
MCP-1 but not KC concentrations. Yet, we are not able to
explain this selective modulation of chemokines by IL-10,
but it may be speculated that, in contrast to the systemicMediators of Inﬂammation 5
MCP-1 concentration, the alveolar macrophages are not the
main source for systemic measured KC levels.
The inﬂux of inﬂammatory cells in the lung following
hemorrhagic shock has been well described and is thought
to be a major contributor to the development of remote
organ dysfunction following trauma [29, 30]. Our data show
that inhalation of IL-10 signiﬁcantly reduces pulmonary
myeloperoxidase activity, an established marker for pul-
monary neutrophil inﬁltration, in shocked animals. Pul-
monary histopathology showed a trend towards a decreased
inﬂux of inﬂammatory cells; however signs of severe pul-
monary injury were not detectable in this early phase. This
is in line with other studies detecting histological evidence of
ARDS usually not before 24hrs after hemorrhagic shock [4].
Overall, the reduced pulmonary inﬂammation is in accor-
dance with other studies showing that IL-10 administration
signiﬁcantly decreased neutrophil inﬁltration in the lung
[3, 31, 32]. The beneﬁcial pulmonary eﬀect of endogenous
IL-10 has also been shown in other animal models [13, 33]
and is further supported by clinical studies which report that
nonsurvivors of ARDS had signiﬁcantly lower levels of IL-10
in the BAL-ﬂuid as compared to survivors [34].
Several features and limitations of our study merit fur-
ther comment. We did not investigate later time points and
one may criticize that inhalative IL-10 administration may
delay but not prevent pulmonary inﬂammation following
hemorrhagic shock. Further, the unchanged systemic con-
centrations of IL-6, KC, and IL-10 do not rule out that other
important mediators in the posttraumatic inﬂammatory
cascade may be altered by inhalative IL-10 and thereby the
susceptibility to infection may again be increased.
In conclusion, this study demonstrates that inhalative IL-
10 reduces pulmonary inﬂammation following hemorrhagic
shock without major alterations in the systemic inﬂamma-
tory response. This may be a valuable therapeutic strat-
egy because inhalative IL-10 administration may solve the
dilemma of the two-edged sword: end organ protection
is possible without altering the systemic inﬂammatory
response and the susceptibility to infection and sepsis.
Nonetheless, further studies are required to elucidate the
complex immunomodulatory action of IL-10 under the con-
dition of hemorrhagic shock.
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